Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Reserve your place

Your stakeholders are key – satisfy all their needs at North America's leading market access and real-world evidence summit.


In today’s complex healthcare environment, meeting the needs of payers, patients and decision-makers is a challenging but crucial task! The only companies to succeed will be those to fully embrace the potential of data and demonstrate the real-value of their drugs.

That’s why Data, Evidence and Access Summit 2017 (Nov 13-14) returns to Philadelphia for a 7th year, bringing with it two days of unmissable insights from the industry's leading market access and real-world evidence experts. On the first day - how to define and deliver value to a range of key stakeholders; while on day two we refine our focus to explore innovative uses of RWE across the company and take a detailed look into new outcomes-based pricing models and access strategies.

This is the only place pharma, payers and stakeholders come together to collaborate and drive the change towards a value-based healthcare system.

Snapshot of out expert speaker line-up

Debbie Drane
Debbie Drane

CSL Behring

SVP Commercial Development

Peter Juhn
Peter Juhn

Amgen

Vice President and Global Head of Value-based Partnerships

Bruce Lavin
Bruce Lavin

UCB

Vice President and Head – Medical Affairs, Neurology Patient Value Unit and Head of External Engagement and Policy

Gergana Zlateva
Gergana Zlateva

Pfizer

Vice President, Oncology Market Access

Don't miss out - register now

Only 2 days left to save $300 with our Early Bird discount. Don't miss out!

Key agenda sections:

Keynotes
12:00 - 12:30

Navigate your way turbulent healthcare landscape, unlock the meaning of true value for your key stakeholders and witness the future of evidence generation.

12:00 - 12:30
Real-world data
12:00 - 12:30

The latest from the FDA & payers, how RWE is transforming development and the next-gen technologies revolutionising data generation and analytical capabilities.

12:00 - 12:30
Market Access
12:00 - 12:30

Prioritise access throughout your organisation, create real value with innovative pricing schemes and prepare your portfolio for value based agreements.

Snapshot of our presenters:

Sandy Leonard
Sandy Leonard

AstraZeneca

Vice President, Medical Evidence and Observational Research

John Bardi
John Bardi

Otsuka

Vice President Public Affairs and Digital Medicine Business Development

Jonathan Jarow
Jonathan Jarow

FDA

Senior Medical Director

Ana Cespedes
Ana Cespedes

EMD Serono

Senior Vice President, Head of Global Market Access & Pricing

Riccardo Perfetti
Riccardo Perfetti

Sanofi

Senior Medical Officer, Vice President Global Medical Affairs, Diabetes Division

Riad Dirani
Riad Dirani

TEVA

VP Global Health Economics and Outcomes Research

Tom Abbott
Thomas Abbott

Astellas

Global Head, Real World Informatics Capabilities and Alliances

Margaret McDonald, PhD
Margaret McDonald, PhD

Pfizer

Senior Director, Real World Data and Analytics, Patient & Health Impact

Debbie Drane
Debbie Drane

CSL Behring

SVP Commercial Development

Edmund Pezalla
Edmund Pezalla

Aetna

Former Vice President for Pharmaceutical Policy and Strategy

Dr. Vidya Raman-Tangella
Vidya Raman-Tangella

UnitedHealthcare

SVP, Head Innovation Center of Excellence

Andy Gunn
Andy Gunn

UCB

Global Head of Evidence Generation Strategy

5 reasons to attend:

1

Crystal clarity. Gain 360-degree vision when navigating the complex US healthcare system – and slash time-to-market.

2

The real-world revolution. Ensure RWE is making its mark throughout your development process, from proof of concept to pragmatic trials

3

Know your value. Understand the true wishes of payers and other key stakeholders – and provide the evidence required to influence their decisions and boost your value proposition

4

Industry-saving pricing models. How outcomes-based agreements can help guarantee reimbursement during times of rising costs and tightening budgets

5

Stakeholders are the key. Why speculate when you can collaborate directly with key payers, FDA and other key influencers, all under one roof?

Don't miss out - register now

Only 2 days left to save $300 with our Early Bird discount. Don't miss out!

Some of the industry leading companies already involved:

abbvie
aetna
amgen
astellas
astra_zeneca
boston_health_economics
bms
bayer
clover_health
csl_behring
emd_serono__teal
sanofi
evidation_health
fda
genentech
novartis
ibm
icer
inc_research
janssen
lilly
united_healthcare
merck
nestle
huron
novo_nordisk
otsuka
parexel
pfizer
popewoodhead
ert
shyft_analytics
teva
ucb
meaning_cloud
zs_associates

Don't miss out - register now

Only 2 days left to save $300 with our Early Bird discount. Don't miss out!

84% of our attendees call our sessions “essential” to their future success
98% rated the program very well run
94% of our attendees say that will likely return next year

What our delegates say:

Got a question? Get in touch below!

James Mackintosh

James Mackintosh

Global project Director | eyeforpharma

Email: jmackintosh@eyeforpharma.com

Phone (US): +1800 814 3459 7163

Phone (Global): +44 (0) 207 375 7163

Ben Parkes

Ben Parkes

Head of Product | eyeforpharma

Email: bparkes@eyeforpharma.com

Phone: +44 (0) 207 422 4346

Don't miss out - register now

Only 2 days left to save $300 with our Early Bird discount. Don't miss out!